Post-Inflammatory Hyperpigmentation (Investigational)
Highly investigational adjunct for refractory PIH; case reports only; sun protection, topical hypopigmenting agents, and chemical peels remain primary.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for post-inflammatory hyperpigmentation. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Какие доказательства существуют?
- Tier C (investigational). Anecdotal only. Evidence-based first-line management is rigorous broad-spectrum sunscreen use, treatment of the underlying inflammation, topical hydroquinone (4 percent) often combined with retinoid and corticosteroid (Kligman regimen), azelaic acid, tranexamic acid (topical or low-dose oral), and for resistant cases chemical peels (glycolic, salicylic) or laser. Many cases also fade spontaneously over 6-24 months.
- Основные риски
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Paradoxical worsening of hyperpigmentation (post-inflammatory hyperpigmentation can be triggered by ANY skin inflammation, including leech bites)
- Permanent scarring at bite sites in patients with darker skin types
- Кому не следует это рассматривать
- Patients with Fitzpatrick skin types IV-VI without first trying medical therapy (high risk of PIH from leech bites themselves)
- Patients who have not had a full trial of sunscreen + topical lighteners for at least 3-6 months
- Patients with active underlying inflammation (the cause must be treated first)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- О чём спросить врача
- Is my hyperpigmentation truly post-inflammatory, or could it be melasma or another pigmentary disorder?
- Have I had a proper trial of sunscreen, hydroquinone, retinoid, and azelaic acid?
- What is the risk that leech bites themselves cause more hyperpigmentation in my skin type?
- Have chemical peels or laser been considered?
- What is the published evidence base for leeches in PIH specifically?
- How will success be measured — colorimetry, photographs, both?
- Когда срочно обратиться за медицинской помощью
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden spread of pigmentation, new dark patches with irregular borders (possible melanoma)
- Rapidly enlarging or asymmetric pigmented lesion
Что это НЕ означает
- It does not mean leech therapy is FDA-cleared for hyperpigmentation — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace sunscreen, topical lighteners, and treatment of the underlying inflammation.
- It does not prevent recurrence if the original inflammatory cause continues.
- It may worsen PIH in darker skin by adding new inflammatory bite sites.
- It does not have controlled-trial evidence and is unlikely to outperform proven topical therapy.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- dermatological
- ICD-10
- L81.9, L81.0
- Safety tier
- medium
Evidence Summary
Post-inflammatory hyperpigmentation, common in Fitzpatrick IV-VI skin, follows acne, eczema, and other inflammatory dermatoses. Management per dermatologic consensus includes strict photoprotection, treating the underlying inflammatory dermatosis, and topical hydroquinone, retinoids, azelaic acid, niacinamide, and chemical peels (with caution in darker skin types). No controlled clinical trial of leech therapy for post-inflammatory hyperpigmentation has been published; its use is investigational and mechanistic only. PIH typically resolves spontaneously over 6-18 months with photoprotection alone, and treatment-resistant cases are rare. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Singh K et al. (2019)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active inflammatory dermatosis at site (treat underlying condition first)
- Recent chemical peel or laser (<6 weeks)
- Fitzpatrick V-VI skin with hypertrophic scar tendency
- Concurrent topical corticosteroid use
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.